This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 266 |
respiratory syndrome | 232 |
supplemental material | 184 |
acute respiratory | 175 |
severe acute | 155 |
virus infection | 142 |
syndrome coronavirus | 140 |
small rnas | 126 |
rna viruses | 122 |
infected cells | 97 |
immune response | 94 |
viral rna | 92 |
middle east | 91 |
gene expression | 88 |
small rna | 84 |
east respiratory | 82 |
influenza viruses | 75 |
rna virus | 68 |
amino acid | 67 |
escherichia coli | 67 |
avian influenza | 66 |
vero cells | 66 |
immune responses | 65 |
public health | 64 |
cov ma | 63 |
cord uid | 62 |
previously described | 62 |
mbio doi | 62 |
doc id | 62 |
cov infection | 61 |
virus replication | 59 |
ebola virus | 59 |
viral replication | 57 |
highly pathogenic | 54 |
cell surface | 54 |
cell responses | 53 |
viral infection | 52 |
data set | 51 |
cell culture | 50 |
mediated ifn | 49 |
ebov gp | 49 |
infected mice | 49 |
dsrna viruses | 47 |
stranded rna | 46 |
innate immune | 46 |
parainfluenza virus | 46 |
respiratory disease | 45 |
performed using | 44 |
virus titers | 44 |
cov nsp | 44 |
see table | 43 |
antiviral activity | 43 |
host response | 43 |
fatty acid | 42 |
room temperature | 42 |
viral genome | 42 |
described previously | 42 |
epithelial cells | 42 |
cell lines | 41 |
cd expression | 41 |
virus type | 41 |
flow cytometry | 40 |
differentially expressed | 40 |
protein kinase | 40 |
bone marrow | 39 |
veroe cells | 39 |
amino acids | 39 |
ko mice | 39 |
united states | 39 |
reverse transcription | 39 |
pandemic influenza | 38 |
dmv formation | 38 |
pl flux | 38 |
time points | 38 |
determine whether | 38 |
novel coronavirus | 38 |
thermo fisher | 38 |
receptor binding | 37 |
time point | 37 |
predict pdf | 37 |
mice infected | 36 |
bovine serum | 36 |
spike protein | 36 |
viroporin domain | 35 |
cdna clone | 35 |
infectious diseases | 35 |
urokinase pathway | 34 |
protein expression | 33 |
linked glycans | 33 |
viral proteins | 33 |
roni cells | 33 |
convalescent plasma | 33 |
pl synthesis | 33 |
closely related | 33 |
respiratory syncytial | 32 |
pkr mrna | 32 |
well plates | 32 |
cell activation | 32 |
syncytial virus | 32 |
human coronavirus | 32 |
weight loss | 31 |
human cells | 31 |
immunodeficiency virus | 31 |
virus infections | 31 |
cell types | 31 |
lgi network | 31 |
cells infected | 31 |
differential expression | 31 |
clinical samples | 31 |
lung injury | 31 |
virus transmission | 31 |
following sars | 30 |
potential pandemic | 30 |
rna polymerase | 30 |
risk assessment | 30 |
type i | 29 |
respiratory tract | 29 |
human immunodeficiency | 29 |
buffered saline | 29 |
infectious cdna | 28 |
dendritic cells | 28 |
open reading | 28 |
significantly higher | 28 |
see also | 28 |
convalescent subjects | 27 |
porcine epidemic | 27 |
research enterprise | 27 |
monoclonal antibody | 27 |
ko cells | 27 |
sars coronavirus | 27 |
phylogenetic analysis | 27 |
genome sequence | 27 |
pdf file | 27 |
genomic rna | 27 |
coronavirus infection | 27 |
host range | 26 |
genome sequences | 26 |
mouse model | 26 |
putative small | 26 |
endoplasmic reticulum | 26 |
ma infection | 26 |
dimer interface | 25 |
data suggest | 25 |
emc infection | 25 |
clinical signs | 25 |
capsid protein | 25 |
pandemic potential | 25 |
veroe tmprss | 25 |
pkr protein | 25 |
nasal swabs | 25 |
tif file | 25 |
unexposed subjects | 25 |
following infection | 25 |
class ii | 24 |
like protease | 24 |
total rna | 24 |
epidemic diarrhea | 24 |
rna synthesis | 24 |
cynomolgus macaques | 24 |
rna loci | 24 |
innate immunity | 24 |
vaccinia virus | 24 |
nipah virus | 24 |
tmprss cells | 24 |
human parainfluenza | 24 |
wt vol | 23 |
deep sequencing | 23 |
accession number | 23 |
lung pathology | 23 |
network analysis | 23 |
dependent rna | 23 |
plasma membrane | 23 |
previously reported | 23 |
bl mefs | 23 |
complement system | 23 |
zippered er | 22 |
antibody titers | 22 |
statistically significant | 22 |
live attenuated | 22 |
reverse genetics | 22 |
igg mbcs | 22 |
combo alum | 22 |
fetal bovine | 22 |
glycan array | 22 |
heparan sulfate | 22 |
genome sequencing | 22 |
seasonal influenza | 22 |
also observed | 22 |
pkr degradation | 21 |
cell epitopes | 21 |
tissue culture | 21 |
protease inhibitor | 21 |
fisher scientific | 21 |
vol vol | 21 |
binding site | 21 |
saudi arabia | 21 |
adaptive immune | 21 |
article may | 21 |
expression levels | 21 |
acute lung | 21 |
host responses | 21 |
health care | 21 |
expression patterns | 21 |
pathogenic avian | 21 |
times postinfection | 21 |
days postinfection | 20 |
signaling pathway | 20 |
immunized mice | 20 |
combo smq | 20 |
human oas | 20 |
virus evolution | 20 |
dromedary camels | 20 |
may also | 20 |
fluorescent protein | 20 |
candida albicans | 20 |
nonstructural protein | 20 |
recombinant viruses | 20 |
viral genomes | 20 |
cd upregulation | 20 |
lysis buffer | 20 |
onward transmission | 20 |
plaque assay | 20 |
class i | 20 |
glycan cap | 19 |
recognition receptors | 19 |
treated control | 19 |
results suggest | 19 |
clinical trials | 19 |
mg kg | 19 |
diarrhea virus | 19 |
hepatitis virus | 19 |
analyzed using | 19 |
blot analysis | 19 |
protein synthesis | 19 |
reverse transcriptase | 19 |
binding domain | 19 |
viroporin activity | 19 |
fusion protein | 19 |
mrna levels | 19 |
gp core | 19 |
membrane structures | 19 |
mammalian cells | 19 |
vaccine development | 18 |
peritoneal macrophages | 18 |
wt mice | 18 |
gene product | 18 |
unknown function | 18 |
mhc class | 18 |
cov pathogenesis | 18 |
knockout mice | 18 |
host cell | 18 |
cov spike | 18 |
western blotting | 18 |
codon usage | 18 |
least one | 18 |
murine coronavirus | 18 |
three times | 18 |
well plate | 18 |
streptococcus equi | 18 |
cells treated | 18 |
varroa mites | 18 |
membrane synthesis | 18 |
national institute | 18 |
bat cells | 18 |
human cases | 18 |
pattern recognition | 18 |
control group | 18 |
type mice | 18 |
strand rna | 18 |
low levels | 18 |
immune system | 18 |
serum samples | 18 |
results indicate | 18 |
large number | 18 |
crystal structure | 18 |
viral infections | 18 |
novel human | 18 |
honey bee | 17 |
signaling pathways | 17 |
i interferon | 17 |
airborne transmission | 17 |
mg ml | 17 |
neuraminidase activity | 17 |
genbank accession | 17 |
antibody responses | 17 |
ferret model | 17 |
nsp viroporin | 17 |
time pcr | 17 |
codon selection | 17 |
viral entry | 17 |
human airway | 17 |
inflammatory cells | 17 |
antiviral drugs | 17 |
disease virus | 17 |
reading frame | 17 |
human infection | 17 |
biosafety level | 17 |
puncta formation | 17 |
vaccine candidate | 17 |
animal model | 17 |
late endosomes | 17 |
immune cells | 17 |
plant viruses | 16 |
previous studies | 16 |
cell immunity | 16 |
pandemic preparedness | 16 |
like receptor | 16 |
st isolates | 16 |
respiratory distress | 16 |
distress syndrome | 16 |
culture medium | 16 |
clinical symptoms | 16 |
ev infection | 16 |
neutralizing antibodies | 16 |
elapsed time | 16 |
green fluorescent | 16 |
severe disease | 16 |
virus glycoprotein | 16 |
complement activation | 16 |
cells expressing | 16 |
infected samples | 16 |
select agent | 16 |
transcriptome sequencing | 16 |
determined using | 16 |
primary antibody | 16 |
lung samples | 16 |
quantitative pcr | 16 |
cultured cells | 16 |
high levels | 16 |
glycan determinants | 16 |
peripheral blood | 16 |
nsp nsp | 16 |
protein levels | 16 |
animal models | 16 |
lps synthesis | 16 |
expressing cells | 16 |
lung disease | 16 |
hela cells | 16 |
cell response | 16 |
viral particles | 16 |
infected animals | 16 |
alphavirus supergroup | 15 |
human respiratory | 15 |
mm tris | 15 |
spike glycoprotein | 15 |
binding sites | 15 |
proteolytic processing | 15 |
increased replication | 15 |
respiratory droplets | 15 |
viral titers | 15 |
respiratory viruses | 15 |
egyptian rousette | 15 |
cell line | 15 |
membrane insertion | 15 |
like viruses | 15 |
reading frames | 15 |
posttranslational control | 15 |
lung tissue | 15 |
lower respiratory | 15 |
host cells | 15 |
dominant negative | 15 |
pkr depletion | 15 |
sequencing analysis | 15 |
rdrp tree | 15 |
national institutes | 15 |
pfu cell | 15 |
specific igg | 15 |
via respiratory | 15 |
fusion proteins | 15 |
viral protein | 15 |
march proteins | 15 |
expression changes | 15 |
viral isolation | 15 |
critical role | 15 |
life technologies | 15 |
bl mice | 15 |
recombinant virus | 15 |
kinase inhibitors | 15 |
adenovirus type | 15 |
rna processing | 15 |
infectious virus | 15 |
inflammatory response | 15 |
statistical analysis | 15 |
viral dna | 15 |
host factors | 15 |
vaccine candidates | 15 |
replication fidelity | 15 |
nucleoside analogues | 14 |
north carolina | 14 |
samples collected | 14 |
infected lysates | 14 |
confocal microscopy | 14 |
microarray data | 14 |
optical density | 14 |
viral sequences | 14 |
wt cells | 14 |
viral isolates | 14 |
viral small | 14 |
plsb activity | 14 |
mbcs reactive | 14 |
present study | 14 |
cytopathic effect | 14 |
cell cultures | 14 |
healthy donors | 14 |
nucleocapsid protein | 14 |
membrane protein | 14 |
disease severity | 14 |
day postinfection | 14 |
tracheal wash | 14 |
host damage | 14 |
function experiments | 14 |
lethal dose | 14 |
gp expression | 14 |
igg titers | 14 |
host genes | 14 |
significant differences | 14 |
case fatality | 14 |
previous work | 14 |
complement pathway | 14 |
mouse strains | 14 |
data indicate | 14 |
western blot | 14 |
complement signaling | 14 |
complete genome | 14 |
coronavirus disease | 14 |
linked immunosorbent | 14 |
coronavirus replication | 14 |
histolytica infection | 14 |
expressing mers | 14 |
scientific catalog | 13 |
related viruses | 13 |
tcid ml | 13 |
bd biosciences | 13 |
mice immunized | 13 |
bacterial infections | 13 |
mouse adenovirus | 13 |
treated ferrets | 13 |
accessory genes | 13 |
mycobacterium tuberculosis | 13 |
virus strain | 13 |
world health | 13 |
equi subsp | 13 |
log fc | 13 |
serum albumin | 13 |
cryptococcal meningitis | 13 |
cleavage site | 13 |
proinflammatory cytokines | 13 |
isolates recovered | 13 |
test compounds | 13 |
accession numbers | 13 |
state growth | 13 |
measles virus | 13 |
segmented filamentous | 13 |
important role | 13 |
ge healthcare | 13 |
ml streptomycin | 13 |
sfcs pbmcs | 13 |
medium containing | 13 |
reactive igg | 13 |
antigen presentation | 13 |
common ancestor | 13 |
treated group | 13 |
acid synthesis | 13 |
active site | 13 |
cmt cells | 13 |
lung lesions | 13 |
rna virome | 13 |
transmission studies | 13 |
neutralizing antibody | 13 |
mouse anti | 13 |
also found | 13 |
health organization | 13 |
restriction sites | 13 |
rpmi medium | 13 |
dna replication | 13 |
fusion promotion | 13 |
nucleic acid | 13 |
oas genes | 12 |
gene products | 12 |
vesicular stomatitis | 12 |
transcriptional regulation | 12 |
viral reads | 12 |
positive cells | 12 |
highly conserved | 12 |
severe respiratory | 12 |
human transmission | 12 |
lookup suppl | 12 |
lung tissues | 12 |
infectious agents | 12 |
stomatitis virus | 12 |
ns protein | 12 |
taken together | 12 |
bat coronaviruses | 12 |
mass spectrometry | 12 |
infected ferrets | 12 |
monoclonal antibodies | 12 |
gof experiments | 12 |
cell lysates | 12 |
data sets | 12 |
cell lysis | 12 |
ml penicillin | 12 |
molecular basis | 12 |
hn mutations | 12 |
nucleoside analogue | 12 |
protective immunity | 12 |
neutral red | 12 |
respiratory virus | 12 |
dependent manner | 12 |
generation sequencing | 12 |
infectious center | 12 |
erasmus mc | 12 |
respiratory droplet | 12 |
structural proteins | 12 |
reactive mbcs | 12 |
neutralizing activity | 12 |
proteasomal degradation | 12 |
viroporin mutants | 12 |
cell entry | 12 |
purified using | 12 |
phylogenetic tree | 12 |
suppl doi | 12 |
hek cells | 12 |
clinical sample | 12 |
surface expression | 12 |
virus entry | 12 |
mouse hepatitis | 12 |
circular profiles | 12 |
thermo scientific | 12 |
immune evasion | 12 |
novel potential | 12 |
motif i | 12 |
nonstructural proteins | 12 |
human infections | 12 |
pandemic pathogen | 12 |
protective equipment | 12 |
host gene | 12 |
previously observed | 12 |
even though | 12 |
pandemic pathogens | 12 |
mers coronavirus | 12 |
binding lectin | 12 |
lc ms | 12 |
horseradish peroxidase | 12 |
graphpad prism | 12 |
filamentous bacteria | 12 |
clinical features | 12 |
length gp | 12 |
virus genome | 12 |
noncoding rnas | 12 |
body weight | 12 |
generated using | 12 |
hiv infection | 12 |
staphylococcus aureus | 12 |
distantly related | 12 |
org lookup | 12 |
sequence alignment | 12 |
systems biology | 11 |
oligoadenylate synthetase | 11 |
accelerating factor | 11 |
nh cl | 11 |
like virus | 11 |
rna release | 11 |
time reverse | 11 |
tumor necrosis | 11 |
animal care | 11 |
inherent safety | 11 |
viral envelope | 11 |
length infectious | 11 |
gof studies | 11 |
secondary antibody | 11 |
sv mefs | 11 |
apis mellifera | 11 |
length cdna | 11 |
sequence data | 11 |
mononuclear cells | 11 |
late times | 11 |
average log | 11 |
goat anti | 11 |
infected patients | 11 |
deficient mice | 11 |
first time | 11 |
mature mirnas | 11 |
annotated loci | 11 |
recent study | 11 |
specific cd | 11 |
binding receptors | 11 |
sequence similarity | 11 |
applied biosystems | 11 |
histocompatibility complex | 11 |
gene sets | 11 |
associated molecular | 11 |
nd nd | 11 |
site ii | 11 |
genomic regions | 11 |
mediated endocytosis | 11 |
envelope glycoproteins | 11 |
fecal samples | 11 |
mm nacl | 11 |
disease control | 11 |
blood mononuclear | 11 |
also thank | 11 |
coronavirus associated | 11 |
provide protection | 11 |
gof research | 11 |
spike gene | 11 |
naturally occurring | 11 |
cd blockade | 11 |
host immune | 11 |
inactivated mers | 11 |
northern blot | 11 |
blood samples | 11 |
ng ml | 11 |
viral pathogens | 11 |
lethal challenge | 11 |
different aivs | 11 |
cellular immune | 11 |
candidate loci | 11 |
mers fl | 11 |
unc health | 11 |
airway epithelial | 11 |
st strains | 11 |
virus ns | 11 |
fatality rate | 11 |
years ago | 11 |
african green | 11 |
henipavirus infection | 11 |
gene function | 11 |
brief exposure | 11 |
sybr green | 11 |
viral pathogenesis | 11 |
major histocompatibility | 11 |
colonized mice | 11 |
pl pro | 10 |
reverse transcribed | 10 |
mouth disease | 10 |
restriction site | 10 |
compared using | 10 |
exposed subjects | 10 |
virus vaccine | 10 |
acid sequence | 10 |
monkey kidney | 10 |
noncoding rna | 10 |
whole blood | 10 |
mirna expression | 10 |
reference genome | 10 |
skin fibroblasts | 10 |
research pause | 10 |
cell viability | 10 |
functional analysis | 10 |
hn protein | 10 |
hong kong | 10 |
dengue virus | 10 |
growth factor | 10 |
using primers | 10 |
replication kinetics | 10 |
influenza infection | 10 |
per year | 10 |
furin cleavage | 10 |
protective efficacy | 10 |
major branches | 10 |
rectal swabs | 10 |
mice lacking | 10 |
copy numbers | 10 |
sequence identity | 10 |
gc content | 10 |
membrane permeability | 10 |
kindly provided | 10 |
membrane vesicles | 10 |
wt nsp | 10 |
medium supplemented | 10 |
positive control | 10 |
cytokine production | 10 |
protease inhibitors | 10 |
target cells | 10 |
tlr signaling | 10 |
global rna | 10 |
immune reconstitution | 10 |
tissue damage | 10 |
overall clinical | 10 |
cells using | 10 |
likely due | 10 |
data demonstrate | 10 |
wide range | 10 |
cells exposed | 10 |
upper respiratory | 10 |
phospholipid synthesis | 10 |
trsv isolates | 10 |
expression profiles | 10 |
see materials | 10 |
results demonstrate | 10 |
virus hemagglutinin | 10 |
pbs containing | 10 |
virus shedding | 10 |
gene set | 10 |
rna interference | 10 |
wash fluid | 10 |
influenza pandemic | 10 |
genetic changes | 10 |
community lai | 10 |
replication complex | 10 |
necrosis factor | 10 |
technical assistance | 10 |
influenza vaccine | 10 |
santa cruz | 10 |
cell death | 10 |
statistical significance | 10 |
secondary structure | 10 |
clinical strains | 10 |
significantly increased | 10 |
catalytic domain | 10 |
mutational robustness | 10 |
new york | 10 |
transiently transfected | 10 |
pcr using | 10 |
integral membrane | 10 |
mm edta | 10 |
superscript iii | 10 |
care workers | 10 |
functional receptor | 9 |
hdpp ki | 9 |
situ hybridization | 9 |
like particles | 9 |
final concentration | 9 |
calcium levels | 9 |
inflammatory cytokines | 9 |
molecular mechanisms | 9 |
analysis revealed | 9 |
mdck cells | 9 |
reconstitution inflammatory | 9 |
receptor signaling | 9 |
thermal stability | 9 |
acp concentrations | 9 |
higher levels | 9 |
measured using | 9 |
signaling cascade | 9 |
candida glabrata | 9 |
increased il | 9 |
pcr analysis | 9 |
ion channel | 9 |
also detected | 9 |
colony collapse | 9 |
virus rdrps | 9 |
droplet transmission | 9 |
mice showed | 9 |
culture supernatants | 9 |
ec values | 9 |
strongly supported | 9 |
small interfering | 9 |
mock infected | 9 |
piv expressing | 9 |
resistant bacteria | 9 |
hyaline membranes | 9 |
luciferase assay | 9 |
increased delivery | 9 |
induce dmv | 9 |
cov replication | 9 |
clinical isolate | 9 |
embryonic fibroblasts | 9 |
provide evidence | 9 |
viruses isolated | 9 |
sequence analysis | 9 |
primary human | 9 |
dna viruses | 9 |
based vaccine | 9 |
antibody response | 9 |
right panel | 9 |
specific antibody | 9 |
mirna precursors | 9 |
health risks | 9 |
rna libraries | 9 |
exon activity | 9 |
mm hepes | 9 |
reactive mbc | 9 |
protein sequences | 9 |
will allow | 9 |
virus groups | 9 |
laboratory workers | 9 |
sequencing reads | 9 |
alveolar macrophages | 9 |
connectivity map | 9 |
small nucleolar | 9 |
viral genes | 9 |
equine encephalitis | 9 |
expressed mirnas | 9 |
treated groups | 9 |
viral mrna | 9 |
matched mock | 9 |
coronavirus nsp | 9 |
pandemic risk | 9 |
increased levels | 9 |
quantitative reverse | 9 |
weak colonies | 9 |
analysis using | 9 |
calcium homeostasis | 9 |
internal proteins | 9 |
coronavirus vaccine | 9 |
rna genome | 9 |
cryptococcus neoformans | 9 |
spr analysis | 9 |
data show | 9 |
antiviral response | 9 |
chain reaction | 9 |
epa adhesins | 9 |
modified eagle | 9 |
oas gene | 9 |
transmissible gastroenteritis | 9 |
cell monolayers | 9 |
deformed wing | 9 |
molecular weight | 9 |
washed twice | 9 |
bee colonies | 9 |
green monkey | 9 |
envelope glycoprotein | 9 |
eagle medium | 9 |
kinase pkr | 9 |
dipeptidyl peptidase | 9 |
increased fidelity | 9 |
virus titration | 9 |
ebov entry | 9 |
quantitative real | 9 |
inflammatory syndrome | 9 |
mock infection | 9 |
encephalitis virus | 9 |
healthy controls | 9 |
immunosorbent assay | 9 |
least three | 9 |
cov pseudovirus | 9 |
highly expressed | 9 |
lung lobes | 9 |
also used | 9 |
considered significant | 9 |
transfected cells | 9 |
nl virus | 9 |
cytoplasmic ca | 9 |
use research | 9 |
pcr system | 9 |
sequencing data | 9 |
rabbit anti | 9 |
either niv | 9 |
viral fusion | 9 |
adapted sars | 9 |
allele frequency | 9 |
cell cross | 9 |
venezuelan equine | 9 |
highly connected | 9 |
antiviral drug | 9 |
three independent | 9 |
rna species | 9 |
cov challenge | 9 |
mice exhibited | 9 |
lethal disease | 9 |
inhibitory effect | 9 |
sindbis virus | 9 |
future studies | 9 |
iu ml | 9 |
wing virus | 9 |
ex vivo | 9 |
fold changes | 9 |
membrane pairing | 8 |
rna polymerases | 8 |
fungal clearance | 8 |
causative agent | 8 |
basal oas | 8 |
human march | 8 |
cov infectious | 8 |
naked rna | 8 |
human coronaviruses | 8 |
sample preparation | 8 |
fatality burden | 8 |
influenza vaccines | 8 |
statistical analyses | 8 |
significantly upregulated | 8 |
ki mice | 8 |
per well | 8 |
bronchoalveolar lavage | 8 |
using anti | 8 |
strongly suggest | 8 |
single lab | 8 |
among rna | 8 |
genetics system | 8 |
associated cryptococcosis | 8 |
significantly decreased | 8 |
bee pollen | 8 |
synthesis pathways | 8 |
virus taxonomy | 8 |
personal protective | 8 |
coronavirus infections | 8 |
cell receptor | 8 |
ecm remodeling | 8 |
serine protease | 8 |
cornell ahdc | 8 |
previous study | 8 |
low ph | 8 |
multiple nucleoside | 8 |
calculated using | 8 |
smegmatis mc | 8 |
provided protection | 8 |
virus particles | 8 |
pfu ml | 8 |
test whether | 8 |
mir hg | 8 |
envelope protein | 8 |
formic acid | 8 |
type response | 8 |
horse population | 8 |
tree topology | 8 |
mrna expression | 8 |
gut microbiota | 8 |
expression data | 8 |
pcr amplification | 8 |
igg levels | 8 |
cov sequences | 8 |
epithelial cell | 8 |
polymerase chain | 8 |
risk factors | 8 |
publicly available | 8 |
receptor cleavage | 8 |
long transcripts | 8 |
gp proteins | 8 |
recombinant parainfluenza | 8 |
dna polymerase | 8 |
two viruses | 8 |
virus growth | 8 |
reaction products | 8 |
rna copy | 8 |
small number | 8 |
may function | 8 |
induced ifn | 8 |
binding intensity | 8 |
combo formulated | 8 |
hn dimer | 8 |
virus clearance | 8 |
sfb colonization | 8 |
factor alpha | 8 |
polyprotein processing | 8 |
viral titer | 8 |
upregulate cd | 8 |
nsp junction | 8 |
independent manner | 8 |
valley fever | 8 |
murine hepatitis | 8 |
consensus sequence | 8 |
two different | 8 |
healthy horses | 8 |
evolutionary relationships | 8 |
risks revisited | 8 |
dmem supplemented | 8 |
mc facility | 8 |
infection model | 8 |
bee viruses | 8 |
available online | 8 |
functional genomics | 8 |
unclear whether | 8 |
recent studies | 8 |
human error | 8 |
evolutionary history | 8 |
heterosubtypic protection | 8 |
array screening | 8 |
pkr ubiquitination | 8 |
membrane fusion | 8 |
replicase proteins | 8 |
zooepidemicus isolates | 8 |
expression vector | 8 |
cdna clones | 8 |
genetic diversity | 8 |
function research | 8 |
endothelial cells | 8 |
secondary structures | 8 |
lysine residues | 8 |
elispot assay | 8 |
rna replication | 8 |
adaptor protein | 8 |
dmem containing | 8 |
secreting cells | 8 |
early viral | 8 |
negative control | 8 |
cd ko | 8 |
oas proteins | 8 |
mouse pkr | 8 |
apical surface | 8 |
inhibitory effects | 8 |
lectin binding | 8 |
sars virus | 8 |
genomic analysis | 8 |
using superscript | 8 |
reported previously | 8 |
virus titer | 8 |
plasmid pbac | 8 |
related signaling | 8 |
much less | 8 |
ringspot virus | 8 |
rna isolation | 8 |
human influenza | 8 |
comparative analysis | 8 |
st strain | 8 |
presentation pathway | 8 |
red blood | 8 |
bat coronavirus | 8 |
human betacoronavirus | 8 |
rift valley | 8 |
viral diversity | 8 |
genes encoding | 8 |
control mice | 8 |
respiratory illness | 8 |
coronavirus nonstructural | 8 |
lung lobe | 8 |
number gse | 8 |
like receptors | 8 |
binding specificity | 8 |
mediated damage | 8 |
recombinant mers | 8 |
enzyme concentrations | 8 |
genomic sequences | 8 |
alexa fluor | 8 |
outer membrane | 8 |
fold change | 8 |
phylogenetic analyses | 8 |
nucleic acids | 8 |
loci overlapped | 8 |
deletion mutants | 8 |
transcriptional control | 8 |
viral rnas | 8 |
least two | 8 |
translation inhibition | 8 |
acquired infection | 8 |
functional annotation | 8 |
beta interferon | 8 |
postdoctoral fellows | 8 |
cd surface | 8 |
future plans | 8 |
transmission via | 8 |
clinical disease | 8 |
lab escape | 8 |
infected ko | 8 |
molecular patterns | 7 |
receptor specificity | 7 |
attenuated viruses | 7 |
ci wt | 7 |
boas gene | 7 |
different viruses | 7 |
salmonella typhi | 7 |
time rt | 7 |
treated cells | 7 |
total number | 7 |
vaccine virus | 7 |
nucleotide diversity | 7 |
upstream regulators | 7 |
pathogenic influenza | 7 |
total pkr | 7 |
opsonizing antibodies | 7 |
network strategy | 7 |
induced acute | 7 |
pfu piv | 7 |
entry requires | 7 |
vaccine viruses | 7 |
ev entry | 7 |
lung sections | 7 |
next day | 7 |
type mefs | 7 |
significant increase | 7 |
activated protein | 7 |
via posttranslational | 7 |
cells per | 7 |
convalescent individuals | 7 |
rna locus | 7 |
infected cell | 7 |
mm sodium | 7 |
type nsp | 7 |
invasive gas | 7 |
detectable virus | 7 |
identified using | 7 |
dna fragments | 7 |
nsp expression | 7 |
regulatory factor | 7 |
virus genomes | 7 |
international committee | 7 |
docx file | 7 |
stimulating factor | 7 |
negative controls | 7 |
simplex virus | 7 |
nucleotide sequence | 7 |
highly susceptible | 7 |
select agents | 7 |
cytosolic pamp | 7 |
live virus | 7 |
marrow cells | 7 |
binding properties | 7 |
mucosal immunity | 7 |
influenza risk | 7 |
selective pressure | 7 |
igg antibody | 7 |
potential targets | 7 |
previous reports | 7 |
sinv replication | 7 |
vero cell | 7 |
gof ppp | 7 |
phosphate buffer | 7 |
cell reactivities | 7 |
life sciences | 7 |
herpes simplex | 7 |
group showed | 7 |
bacterial coinfections | 7 |
catb independence | 7 |
vp antibody | 7 |
mutation rate | 7 |
clinical scores | 7 |
value represents | 7 |
time course | 7 |
lps flux | 7 |
structural basis | 7 |
genome browser | 7 |
hplc ms | 7 |
virus isolation | 7 |
entamoeba histolytica | 7 |
new human | 7 |
increased resistance | 7 |
common ancestry | 7 |
inflammatory responses | 7 |
genomic sequence | 7 |
rabbit polyclonal | 7 |
long ncrnas | 7 |
glycans present | 7 |
nucleotide sequences | 7 |
bacterial infection | 7 |
pedv pc | 7 |
purinergic signaling | 7 |
main protease | 7 |
similar results | 7 |
positive signal | 7 |
red arrows | 7 |
viral genomic | 7 |
endosomal acidification | 7 |
recently reported | 7 |
per group | 7 |
pcr assay | 7 |
origin influenza | 7 |
mrna bound | 7 |
previously shown | 7 |
amplicon sequencing | 7 |
transcriptional changes | 7 |
sinv infection | 7 |
ifn induction | 7 |
step rt | 7 |
cubic membranes | 7 |
serial dilutions | 7 |
complement deposition | 7 |
interferon production | 7 |
biomedical research | 7 |
nucleolar rnas | 7 |
standard deviation | 7 |
rna silencing | 7 |
coronavirus rna | 7 |
mice compared | 7 |
crystal violet | 7 |
bhk cells | 7 |
healthy donor | 7 |
viral glycoproteins | 7 |
induce ifn | 7 |
interferon regulatory | 7 |
virus production | 7 |
replicate samples | 7 |
primer sequences | 7 |
protein may | 7 |
expression values | 7 |
human lung | 7 |
use committee | 7 |
sirnas targeting | 7 |
infection models | 7 |
myotis lucifugus | 7 |
sublethal dose | 7 |
like coronavirus | 7 |
immunoblot analysis | 7 |
based vaccines | 7 |
multiple cell | 7 |
inhibitor cocktail | 7 |
patient plasma | 7 |
viruses evolved | 7 |
reagent program | 7 |
human sars | 7 |
respiratory coronavirus | 7 |
expression vectors | 7 |
antiviral immunity | 7 |
results suggested | 7 |
host defense | 7 |
new coronavirus | 7 |
rotavirus nsp | 7 |
infectious clone | 7 |
icelandic isolates | 7 |
acid residues | 7 |
like domain | 7 |
nasal discharge | 7 |
confidence interval | 7 |
tobacco ringspot | 7 |
high concentrations | 7 |
ht sequencing | 7 |
rna transcriptome | 7 |
fever virus | 7 |
cytotoxic effects | 7 |
specific antibodies | 7 |
days later | 7 |
pseudotyped viral | 7 |
natural host | 7 |
novel small | 7 |
cell subsets | 7 |
heavy chain | 7 |
immune cell | 7 |
jackson laboratories | 7 |
lysosomal degradation | 7 |
streptococcus pyogenes | 7 |
based surveillance | 7 |
enhanced green | 7 |
nasal washes | 7 |
bronx zoo | 7 |
nsp mda | 7 |
sample collection | 7 |
well understood | 7 |
agent theft | 7 |
directed mutagenesis | 7 |
remains unclear | 7 |
attachment receptor | 7 |
analysis showed | 7 |
opsonophagocytic killing | 7 |
minimally pathogenic | 7 |
assessed using | 7 |
hcv patient | 7 |
cell type | 7 |
protective immune | 7 |
extracted using | 7 |
medical center | 7 |
better understand | 7 |
dependent protein | 7 |
breast cancer | 7 |
better understanding | 7 |
driving force | 7 |
smq adjuvant | 7 |
hiv activity | 7 |
per person | 7 |
significantly lower | 7 |
bio basic | 7 |
mrna level | 7 |
proteins encoded | 7 |
entry mediated | 7 |
rna replicons | 7 |
bat roni | 7 |
upregulated cd | 7 |
cytoplasmic calcium | 7 |
genetic analysis | 7 |
pore size | 7 |
protein degradation | 7 |
growth kinetics | 7 |
vascular permeability | 7 |
receptor avidity | 7 |
left panel | 7 |
envelope proteins | 7 |
mers ma | 7 |
oas protein | 7 |
expressed genes | 7 |
eptesicus fuscus | 7 |
lysis assay | 7 |
purinergic receptor | 7 |
term passage | 7 |
acid identity | 7 |
two independent | 7 |
human glycoproteins | 7 |
rna expression | 7 |
time quantitative | 7 |
stimulated genes | 7 |
viral load | 7 |
sequence homology | 6 |
infectious disease | 6 |
enterica serovar | 6 |
cells pretreated | 6 |
virus may | 6 |
niv infection | 6 |
virus transfer | 6 |
derived protein | 6 |
red asterisks | 6 |
liquid chromatography | 6 |
asymptomatic spread | 6 |
significant reduction | 6 |
resident horses | 6 |
laboratory escape | 6 |
hn mutation | 6 |
clinical trial | 6 |
virus load | 6 |
honey bees | 6 |
human services | 6 |
severe covid | 6 |
blocks sars | 6 |
tlr agonist | 6 |
infectious dose | 6 |
cells ml | 6 |
conformational changes | 6 |
may play | 6 |
set enrichment | 6 |
negative mutants | 6 |
laboratory strains | 6 |
icelandic horse | 6 |
icosahedral capsids | 6 |
animal species | 6 |
involving pathogens | 6 |
sa nsp | 6 |
secondary antibodies | 6 |
united kingdom | 6 |
sample sc | 6 |
unpublished data | 6 |
cd mimic | 6 |
increased doses | 6 |
rneasy minikit | 6 |
rectal swab | 6 |
rna helicase | 6 |
dna fragment | 6 |
novel avian | 6 |
immunofluorescence assay | 6 |
viral gene | 6 |
human mers | 6 |
naive mice | 6 |
infected individuals | 6 |
short reads | 6 |
type fimbriae | 6 |
activated macrophages | 6 |
neutralization activity | 6 |
mbc formation | 6 |
hcq sulfate | 6 |
washed times | 6 |
cell differentiation | 6 |
pcr assays | 6 |
human pathogens | 6 |
low concentrations | 6 |
primary peritoneal | 6 |
salivary gland | 6 |
completely blocked | 6 |
log fold | 6 |
ring domain | 6 |
pathogenic outcomes | 6 |
infected wild | 6 |
membrane profiles | 6 |
systematic review | 6 |
novel viruses | 6 |
cell lysate | 6 |
different expression | 6 |
nervous system | 6 |
annotated small | 6 |
independent experiments | 6 |
choriomeningitis virus | 6 |
rna recombination | 6 |
rna transcripts | 6 |
signaling cascades | 6 |
derived small | 6 |
confirmed cases | 6 |
fidelity replication | 6 |
doublestranded rna | 6 |
protein interactions | 6 |
broad range | 6 |
sn antibody | 6 |
specific primer | 6 |
sequencing technology | 6 |
adoptive transfer | 6 |
aids research | 6 |
alveolar damage | 6 |
nih grant | 6 |
rrna degradation | 6 |
march inhibits | 6 |
also contribute | 6 |
genes related | 6 |
global host | 6 |
million years | 6 |
recent years | 6 |
funding pause | 6 |
also present | 6 |
infection results | 6 |
stranded dna | 6 |
ifn treatment | 6 |
rotavirus infection | 6 |
acid sequences | 6 |
hendra virus | 6 |
serially diluted | 6 |
molecular markers | 6 |
replication complexes | 6 |
also performed | 6 |
release reports | 6 |
emc induced | 6 |
patience genome | 6 |
lethally infected | 6 |
culture plates | 6 |
boas mrna | 6 |
studies will | 6 |
protease sensitivity | 6 |
dual use | 6 |
human dpp | 6 |
will help | 6 |
protein nsp | 6 |
electron microscopy | 6 |
genome replication | 6 |
clinical outcome | 6 |
blood cells | 6 |
culture adaptation | 6 |
picornavirus supergroup | 6 |
lymphocytic choriomeningitis | 6 |
glutamic acid | 6 |
cell cycle | 6 |
infected hek | 6 |
critically ill | 6 |
newly discovered | 6 |
nsp cleavage | 6 |
glycan interaction | 6 |
point mutation | 6 |
previous report | 6 |
statistical difference | 6 |
also showed | 6 |
necessarily reflect | 6 |
factors associated | 6 |
mice deficient | 6 |
also examined | 6 |
dsrna virus | 6 |
aged mice | 6 |
cells showed | 6 |
streptococcus pneumoniae | 6 |
within branch | 6 |
later times | 6 |
tested using | 6 |
among different | 6 |
virus rdrp | 6 |
fresh medium | 6 |
dmv biogenesis | 6 |
salmonella enterica | 6 |
roll capsid | 6 |
allowed us | 6 |
marburg virus | 6 |
respiratory function | 6 |
experiments using | 6 |
influenza infections | 6 |
species transmission | 6 |
mbc populations | 6 |
human pbmcs | 6 |
biased cross | 6 |
expression omnibus | 6 |
also table | 6 |
function studies | 6 |
disease following | 6 |
animal reservoir | 6 |
investigated whether | 6 |
recently shown | 6 |
rna secondary | 6 |
plasma samples | 6 |
circular view | 6 |
reaction mixture | 6 |
viral evolution | 6 |
acp species | 6 |
similar levels | 6 |
molecular biology | 6 |
containing fbs | 6 |
serum neutralization | 6 |
pathogenic viruses | 6 |
type virus | 6 |
two families | 6 |
ab levels | 6 |
reverse primer | 6 |
hydroxychloroquine sulfate | 6 |
flow cell | 6 |
human virus | 6 |
fuscus skin | 6 |
coli lysis | 6 |
linked glycan | 6 |
adapted strains | 6 |
forward primer | 6 |
constructed using | 6 |
igg antibodies | 6 |
haplotype network | 6 |
ucsc genome | 6 |
microrna host | 6 |
collaborative cross | 6 |
tuberculosis infection | 6 |
cm flask | 6 |
veterinary institute | 6 |
interfering rna | 6 |
institutional review | 6 |
cleaving nsp | 6 |
different cell | 6 |
culture isolates | 6 |
lion keepers | 6 |
virus vaccines | 6 |
higher affinity | 6 |
adaptor proteins | 6 |
percent gc | 6 |
type iii | 6 |
data indicated | 6 |
via transcriptional | 6 |
single jelly | 6 |
human health | 6 |
antiviral effect | 6 |
binding proteins | 6 |
increased expression | 6 |
virus expressing | 6 |
monitoring select | 6 |
rotavirus nonstructural | 6 |
secondary bacterial | 6 |
march expression | 6 |
regulatory protein | 6 |
adaptive immunity | 6 |
sequences obtained | 6 |
prism software | 6 |
human epithelial | 6 |
mouse reference | 6 |
complex class | 6 |
minor allele | 6 |
life cycle | 6 |
delta inulin | 6 |
virus isolates | 6 |
actin filaments | 6 |
sample buffer | 6 |
endosomal maturation | 6 |
lethal infection | 6 |
vortex mixing | 6 |
nonhuman primates | 6 |
march blocks | 6 |
infection date | 6 |
protein structure | 6 |
might also | 6 |
coronavirus emc | 6 |
approved drugs | 6 |
per sample | 6 |
using veroe | 6 |
disease outcomes | 6 |
specific mutations | 6 |
molecularly based | 6 |
paralysis virus | 6 |
attenuated vaccines | 6 |
mycobacteriophage patience | 6 |
emerging human | 6 |
serum igg | 6 |
genetic variation | 6 |
assay using | 6 |
two compounds | 6 |
antiviral candidates | 6 |
lethal mutagenesis | 6 |
two proteins | 6 |
type infection | 6 |
rousettus aegyptiacus | 6 |
coding genes | 6 |
reactive antibodies | 6 |
cell reactivity | 6 |
related genes | 6 |
kidney cells | 6 |
traf expression | 6 |
candidate vaccine | 6 |
pathogen recognition | 6 |
review board | 6 |
monolayer culture | 6 |
nonessential amino | 6 |
throughout iceland | 6 |
rna genomes | 6 |
high sequence | 6 |
diffuse alveolar | 6 |
additional genes | 6 |
airway epithelium | 6 |
mouse igg | 6 |
kda gp | 6 |
graduate students | 6 |
host transcription | 6 |
uniquely mapped | 6 |
data presented | 6 |
conserved among | 6 |
rna cloning | 6 |
may help | 6 |
genomic characterization | 6 |
respiratory tracts | 6 |
dependent entry | 6 |
deletion mutant | 6 |
gel electrophoresis | 6 |
ammonium chloride | 6 |
splice sites | 6 |
order bunyavirales | 6 |
two time | 6 |
sn titers | 6 |
significantly different | 6 |
wild type | 6 |
flavivirus supergroup | 6 |
polyacrylamide gel | 6 |
ppgpp concentrations | 6 |
entry receptors | 6 |
coding sequences | 6 |
uninfected cells | 6 |
glycans attached | 6 |
glycan sites | 6 |
honeybee colonies | 6 |
serovar typhi | 6 |
fusion complex | 6 |
viruses infecting | 6 |
initiation factor | 6 |
central nervous | 6 |
sequencing technologies | 6 |
microbial pathogenesis | 6 |
experimental infection | 6 |
genes associated | 6 |
ec value | 6 |
proteolytic cleavage | 6 |
relationships among | 6 |
entry depends | 6 |
human emergence | 6 |
infected pigs | 6 |
growth medium | 5 |
expression signature | 5 |
human cell | 5 |
infection compared | 5 |
disease pathogenesis | 5 |
research intended | 5 |
nonhuman primate | 5 |
inhibits viral | 5 |
rdrp branch | 5 |
viral sequence | 5 |
protein translation | 5 |
als proteins | 5 |
infected wt | 5 |
cellular debris | 5 |
cynomolgus macaque | 5 |
genome annotation | 5 |
dna libraries | 5 |
complex traits | 5 |
induced lung | 5 |
artificial chromosome | 5 |
upstream regulator | 5 |
pmol od | 5 |
synthesis pathway | 5 |
gp glycosylation | 5 |
cause disease | 5 |
untreated cells | 5 |
mirna small | 5 |
viral populations | 5 |
bat oas | 5 |
control sirna | 5 |
clathrin heavy | 5 |
consensus sequences | 5 |
oas fusion | 5 |
immune signaling | 5 |
guinea pigs | 5 |
ns mutations | 5 |
cell epitope | 5 |
myeloid cells | 5 |
targeting rab | 5 |
intranasal route | 5 |
general population | 5 |
cdna libraries | 5 |
baltimore classes | 5 |
transcription factor | 5 |
mumps virus | 5 |
reactive cd | 5 |
icelandic horses | 5 |
identified several | 5 |
newly generated | 5 |
different groups | 5 |
red infectious | 5 |
humoral responses | 5 |
dendritic cell | 5 |
murine model | 5 |
virus rna | 5 |
exact test | 5 |
lpxc concentrations | 5 |
annotated genes | 5 |
sars pandemic | 5 |
assay performed | 5 |
surface hs | 5 |
modified small | 5 |
throughput sequencing | 5 |
least identical | 5 |
well tolerated | 5 |
human receptors | 5 |
cytokine secretion | 5 |
nsp protein | 5 |
care facilities | 5 |
genomic region | 5 |
cell fusion | 5 |
honeybee viruses | 5 |
structural modeling | 5 |
min hold | 5 |
associated mutations | 5 |
pedv strain | 5 |
virus pathogenesis | 5 |
also known | 5 |
abundant small | 5 |
stem cells | 5 |
glycoprotein gp | 5 |
signal sequence | 5 |
immunofluorescence microscopy | 5 |
subcellular localization | 5 |
sucrose gradients | 5 |
order nidovirales | 5 |
standard deviations | 5 |
i signaling | 5 |
induced disease | 5 |
results indicated | 5 |
lung hemorrhage | 5 |
intestinal microbiota | 5 |
uncleaved nsp | 5 |
two groups | 5 |
unc irb | 5 |
modified vaccinia | 5 |
several studies | 5 |
correlation coefficient | 5 |
pathogen interactions | 5 |
also likely | 5 |
newcastle disease | 5 |
reportedly active | 5 |
macaque model | 5 |
showed increased | 5 |
respiratory secretions | 5 |
results obtained | 5 |
mapped reads | 5 |
virus disease | 5 |
er oas | 5 |
transcript expression | 5 |
institutional animal | 5 |
virus research | 5 |
branch consists | 5 |
protein fraction | 5 |
gene sequences | 5 |
associated coronavirus | 5 |
bars represent | 5 |
gp shedding | 5 |
potential fatalities | 5 |
converting enzyme | 5 |
also included | 5 |
viral transport | 5 |
mers virus | 5 |
march affects | 5 |
protein might | 5 |
reference reagent | 5 |
bacterial artificial | 5 |
human enterovirus | 5 |
remains unknown | 5 |
eukaryotic rna | 5 |
calf serum | 5 |
interaction networks | 5 |
different species | 5 |
may provide | 5 |
mortality rate | 5 |
state levels | 5 |
geometric mean | 5 |
lymph nodes | 5 |
gene sharing | 5 |
mouse proteins | 5 |
close proximity | 5 |
single dose | 5 |
physical distancing | 5 |
bat species | 5 |
dna virus | 5 |
lung cells | 5 |
commonly used | 5 |
genetic background | 5 |
quantified using | 5 |
necessarily represent | 5 |
reads mapped | 5 |
health benefits | 5 |
created using | 5 |
total rnas | 5 |
flowjo software | 5 |
superfamily helicase | 5 |
antiviral treatment | 5 |
ron fouchier | 5 |
emc strain | 5 |
pkr activation | 5 |
prompted us | 5 |
strand synthesis | 5 |
killing assay | 5 |
peroxisome proliferator | 5 |
recombination event | 5 |
vaccine strain | 5 |
fold higher | 5 |
buffered formalin | 5 |
infected subjects | 5 |
multiple sequence | 5 |
coding regions | 5 |
purifying respirators | 5 |
changes inventory | 5 |
relatively low | 5 |
binary gradient | 5 |
protein abundance | 5 |
plant virus | 5 |
circular double | 5 |
polyclonal anti | 5 |
bsl conditions | 5 |
array data | 5 |
human adenovirus | 5 |
cryptococcal disease | 5 |
gastroenteritis virus | 5 |
pathological host | 5 |
gas vaccine | 5 |
data using | 5 |
diverse viruses | 5 |
investigate whether | 5 |
relatively high | 5 |
start positions | 5 |
dq bsa | 5 |
synonymous codon | 5 |
cells compared | 5 |
trained innate | 5 |
pcr products | 5 |
fidelity variants | 5 |
acid changes | 5 |
ma pathogenesis | 5 |
ebov igg | 5 |
elispot assays | 5 |
previously published | 5 |
symptom onset | 5 |
immortalized cells | 5 |
min using | 5 |
potent activity | 5 |
significantly reduced | 5 |
sister group | 5 |
sequences available | 5 |
national center | 5 |
identical experiments | 5 |
deoxy sequencing | 5 |
alveolar fibrin | 5 |
showed reduced | 5 |
collapse disorder | 5 |
cov genome | 5 |
virus biology | 5 |
infection may | 5 |
strong evidence | 5 |
vaccine efficacy | 5 |
hcv patients | 5 |
risk assessments | 5 |
sanger sequencing | 5 |
strain pc | 5 |
cell signaling | 5 |
neutralization assay | 5 |
cycle threshold | 5 |
arteritis virus | 5 |
performance characteristics | 5 |
plaque assays | 5 |
confocal microscope | 5 |
zoonotic influenza | 5 |
horseshoe bats | 5 |
target genes | 5 |
flow cytometer | 5 |
cell suspension | 5 |
wound healing | 5 |
ml min | 5 |
changes induced | 5 |
promoter region | 5 |
postmortem examination | 5 |
using ngs | 5 |
asymptomatic patients | 5 |
fruit bats | 5 |
enrichment analysis | 5 |
weak immune | 5 |
form puncta | 5 |
low probability | 5 |
functional characterization | 5 |
primer set | 5 |
mouse models | 5 |
data available | 5 |
including influenza | 5 |
complete protection | 5 |
remove debris | 5 |
potential impact | 5 |
nasal turbinate | 5 |
inherently safe | 5 |
aspartic acid | 5 |
among humans | 5 |
water emulsion | 5 |
levels wane | 5 |
epa proteins | 5 |
experiments will | 5 |
almost completely | 5 |
antibody neutralization | 5 |
sinv genome | 5 |
gp processing | 5 |
virus challenge | 5 |
data representing | 5 |
mutation rates | 5 |
vast majority | 5 |
considered statistically | 5 |
viruses bearing | 5 |
host interactions | 5 |
live cells | 5 |
vaccine protects | 5 |
data collection | 5 |
human viruses | 5 |
pseudoparticles bearing | 5 |
many cases | 5 |
bat sars | 5 |
worker bees | 5 |
infection resulted | 5 |
day period | 5 |
mmr vaccine | 5 |
error bars | 5 |
simian virus | 5 |
transgenic mice | 5 |
human monoclonal | 5 |
hn mutants | 5 |
cellular proteins | 5 |
mutant viruses | 5 |
library construction | 5 |
blue module | 5 |
much higher | 5 |
dna yield | 5 |
study design | 5 |
respiratory signs | 5 |
inflammatory cell | 5 |
protein inhibits | 5 |
assays using | 5 |
virus release | 5 |
dsrna binding | 5 |
nasal swab | 5 |
macrophage colony | 5 |
effective antiviral | 5 |
plasminogen activator | 5 |
gof mutations | 5 |
cells well | 5 |
different mechanisms | 5 |
highly sensitive | 5 |
perivascular inflammation | 5 |
using reverse | 5 |
reads mapping | 5 |
nih national | 5 |
culture conditions | 5 |
highly divergent | 5 |
sense rna | 5 |
np pool | 5 |
renal failure | 5 |
also provide | 5 |
identify potential | 5 |
fold increase | 5 |
create novel | 5 |
lgi networks | 5 |
collected lysates | 5 |
recombinant pedv | 5 |
macaques inoculated | 5 |
coli fimh | 5 |
biosafety measures | 5 |
sequence information | 5 |
dnase i | 5 |
center assay | 5 |
synthetic biology | 5 |
bal fluid | 5 |
dimethyl sulfoxide | 5 |
size distribution | 5 |
new virus | 5 |
viral population | 5 |
like bodies | 5 |
binding protein | 5 |
polar interactions | 5 |
gamma interferon | 5 |
related virus | 5 |
significantly less | 5 |
equine arteritis | 5 |
signaling molecules | 5 |
high level | 5 |
complex formation | 5 |
cho cells | 5 |
opposing monomer | 5 |
subgenomic rna | 5 |
internal standards | 5 |
serpine expression | 5 |
infection using | 5 |
reference sequence | 5 |
lung following | 5 |
host ranges | 5 |
severe lung | 5 |
complete medium | 5 |
remained stable | 5 |
chain acp | 5 |
cell supernatants | 5 |
first days | 5 |
expression analysis | 5 |
increased survival | 5 |
host receptor | 5 |
th th | 5 |
cell recognition | 5 |
genome segments | 5 |
leukemia virus | 5 |
plasmid dnas | 5 |
nonfat milk | 5 |
nasal turbinates | 5 |
analogue resistance | 5 |
asterisks indicate | 5 |
maximum likelihood | 5 |
innate response | 5 |
mouse monoclonal | 5 |
scientific community | 5 |
agilent bioanalyzer | 5 |
cells produced | 5 |
capsid proteins | 5 |
respiratory samples | 5 |
membrane modifications | 5 |
culture infective | 5 |
extracellular atp | 5 |
humanized plasminogen | 5 |
varroa jacobsoni | 5 |
emerging viruses | 5 |
cells stably | 5 |
state university | 5 |
bacterial strains | 5 |
quantitative rt | 5 |
isolated pbmcs | 5 |
group ii | 5 |
cs values | 5 |
single virus | 5 |
cancer cells | 5 |
previously identified | 5 |
biological processes | 5 |
michael imperiale | 5 |
essential medium | 5 |
purification kit | 5 |
aligned using | 5 |
first step | 5 |
hyaline membrane | 5 |
right lung | 5 |
od value | 5 |
completely blocks | 5 |
lung immunopathology | 5 |
containing mm | 5 |
prepared using | 5 |
amplified using | 5 |
associated protein | 5 |
enzymatic activity | 5 |
derived macrophages | 5 |
coa concentrations | 5 |
fetal calf | 5 |
findings suggest | 5 |
eight hours | 5 |
showed significantly | 5 |
acp levels | 5 |
adaptive mutations | 5 |
mm ammonium | 5 |
fimh adhesin | 5 |
glycosylation site | 5 |
highly virulent | 5 |
using standard | 5 |
virus attachment | 5 |
mechanisms regulating | 5 |
current study | 5 |
mirnas showed | 5 |
global health | 5 |
strong colonies | 5 |
igg subclasses | 5 |
common feature | 5 |
diagnostic tests | 5 |
antiviral role | 5 |
pseudotyped virus | 5 |
icelandic veterinary | 5 |
mouse lung | 5 |
vitro stimulation | 5 |
disease among | 5 |
cell memory | 5 |
transcription factors | 5 |
cohort study | 5 |
different adjuvants | 5 |
cocktail kit | 5 |
one health | 5 |
renilla luciferase | 5 |
high titers | 5 |
activated receptor | 5 |
growth rates | 4 |
response framework | 4 |
linear model | 4 |
erasmus medical | 4 |
scientific value | 4 |
mutational changes | 4 |
low frequencies | 4 |
preparation kit | 4 |
response induced | 4 |
perinuclear region | 4 |
also data | 4 |
recently emerged | 4 |
melting temperature | 4 |
cell layers | 4 |
stage lung | 4 |
ebov vp | 4 |
san diego | 4 |
lethal infections | 4 |
transmembrane domains | 4 |
phosphate broth | 4 |
laboratories involved | 4 |
recombinant mouse | 4 |
drug resistance | 4 |
annotations among | 4 |
activated cell | 4 |
membrane formation | 4 |
human peripheral | 4 |
pedv avct | 4 |
library preparation | 4 |
almost entirely | 4 |
blood cell | 4 |
discovered coronavirus | 4 |
infecting aivs | 4 |
many rna | 4 |
gp envelope | 4 |
gross lesions | 4 |
standard protocol | 4 |
without affecting | 4 |
early endosomes | 4 |
linked glycosylation | 4 |
causes pkr | 4 |
ill patients | 4 |
antiviral effects | 4 |
several clinical | 4 |
without ca | 4 |
infectious clones | 4 |
small nuclear | 4 |
i fusion | 4 |
transmission experiments | 4 |
known viral | 4 |
also shown | 4 |
natural sars | 4 |
whitney test | 4 |
degrade pkr | 4 |
respiratory tissues | 4 |
findings indicate | 4 |
ace receptor | 4 |
two washes | 4 |
genes involved | 4 |
molecularbased surveillance | 4 |
host tissues | 4 |
safe vaccine | 4 |
potential exposure | 4 |
associated ring | 4 |
observed increased | 4 |
ferret gain | 4 |
mhv nsp | 4 |
protects mice | 4 |
experiments involving | 4 |
ko roni | 4 |
type mda | 4 |
ms system | 4 |
natural infection | 4 |
immunity may | 4 |
decreased expression | 4 |
va rnas | 4 |
data suggested | 4 |
function debate | 4 |
bacterial cell | 4 |
associated herpesvirus | 4 |
positively stained | 4 |
one host | 4 |
type strain | 4 |
intestinal colonization | 4 |
major tail | 4 |
ferret passage | 4 |
scale changes | 4 |
enhanced chemiluminescence | 4 |
specific infectivity | 4 |
possible role | 4 |
sialic acid | 4 |
molecular evolutionary | 4 |
genome organization | 4 |
enzyme activity | 4 |
module eigengene | 4 |
cause damage | 4 |
experimentally observed | 4 |
mouse oas | 4 |
three major | 4 |
largest rna | 4 |
free water | 4 |
three oas | 4 |
genbank id | 4 |
ferret adapted | 4 |
villous enterocytes | 4 |
gc contents | 4 |
efficient transmission | 4 |
antibody specific | 4 |
observed following | 4 |
key role | 4 |
protein secretion | 4 |
evolutionary genetics | 4 |
animal experiments | 4 |
sinv genomic | 4 |
mediated disease | 4 |
pathway may | 4 |
viruses may | 4 |
antiserum sensitivity | 4 |
lining epithelium | 4 |
significant upregulation | 4 |
west nile | 4 |
cells transfected | 4 |
mouse cells | 4 |
intestinal epithelial | 4 |
study represents | 4 |
data availability | 4 |
mutations found | 4 |
cerebrospinal fluid | 4 |
single mutations | 4 |
nonstructural glycoprotein | 4 |
also increased | 4 |
mycobacteriophage relatives | 4 |
complement protein | 4 |
cause severe | 4 |
translation initiation | 4 |
nrc symposium | 4 |
periodate oxidation | 4 |
chapel hill | 4 |
close mycobacteriophage | 4 |
reaction mixtures | 4 |
uropathogenic escherichia | 4 |
enhanced disease | 4 |
synthesis via | 4 |
receptor recognition | 4 |
molecular masses | 4 |
ngs data | 4 |
plasma therapy | 4 |
independent tests | 4 |
cells transiently | 4 |
reads directly | 4 |
ev uncoating | 4 |
significant difference | 4 |
coronavirus spike | 4 |
mass spectrometer | 4 |
conjugated secondary | 4 |
fatal human | 4 |
newly identified | 4 |
covalent bond | 4 |
coronaviruses shows | 4 |
dotted line | 4 |
fibrin deposition | 4 |
endosomal receptor | 4 |
stranded rnadependent | 4 |
human metapneumovirus | 4 |
biological properties | 4 |
interferon induction | 4 |
lysine cluster | 4 |
data represent | 4 |
much lower | 4 |
cov outbreak | 4 |
gp interactions | 4 |
severely ill | 4 |
may represent | 4 |
igg response | 4 |
acid pathway | 4 |
endosomal cathepsins | 4 |
rabies virus | 4 |
infected mouse | 4 |
step real | 4 |
type ii | 4 |
protein involved | 4 |
highly diverse | 4 |
stable cells | 4 |
intracellular rna | 4 |
chemokine levels | 4 |
charles river | 4 |
novel virus | 4 |
immune suppression | 4 |
studies using | 4 |
evolutionary model | 4 |
previous microarray | 4 |
transcriptase pcr | 4 |
increasing amounts | 4 |
molecular characterization | 4 |
strong immune | 4 |
indirect contact | 4 |
risk analysis | 4 |
marrow dendritic | 4 |
upregulated genes | 4 |
wt sv | 4 |
across different | 4 |
across iceland | 4 |
polymerase activity | 4 |
unintended consequences | 4 |
leukemia cells | 4 |
fecal specimens | 4 |
qpcr assay | 4 |
pfu per | 4 |
amebic infection | 4 |
emerging infectious | 4 |
vaccine design | 4 |
derived dendritic | 4 |
adapted mers | 4 |
nile virus | 4 |
categorical imperative | 4 |
draft genome | 4 |
gp gp | 4 |
virus capsid | 4 |
sodium chlorate | 4 |
virus propagation | 4 |
cluster i | 4 |
potential host | 4 |
negative impact | 4 |
parental virus | 4 |
expiratory flow | 4 |
genomic distribution | 4 |
protein level | 4 |
class pathogen | 4 |
protein alpha | 4 |
using raxml | 4 |
several viruses | 4 |
protein binds | 4 |
mouse oasl | 4 |
previously unannotated | 4 |
fg program | 4 |
genes include | 4 |
strongly downregulated | 4 |
serum antibodies | 4 |
pkr steady | 4 |
log tcid | 4 |
mutations associated | 4 |
data strongly | 4 |
cold pbs | 4 |
peak viral | 4 |
enveloped viruses | 4 |
crispr cas | 4 |
viral spike | 4 |
antiviral efficacies | 4 |
cell growth | 4 |
infectious respiratory | 4 |
using flowjo | 4 |
swine industry | 4 |
hi dcs | 4 |
adult bees | 4 |
coronavirus causes | 4 |
also possible | 4 |
multiple comparisons | 4 |
pandemic threats | 4 |
data support | 4 |
flow cytometric | 4 |
infected lung | 4 |
ngs within | 4 |
tissue sections | 4 |
march also | 4 |
pulmonary disease | 4 |
invasive lethal | 4 |
two additional | 4 |
mammalian host | 4 |
close contact | 4 |
provide insight | 4 |
vaccine expressing | 4 |
horizontal virus | 4 |
rapid response | 4 |
polyclonal antibody | 4 |
cov infections | 4 |
altered glycosylation | 4 |
coronavirus papain | 4 |
inactivating substitutions | 4 |
combination therapy | 4 |
antigenic variation | 4 |
virus antigen | 4 |
unclassified viruses | 4 |
positive selection | 4 |
mice following | 4 |
cells expressed | 4 |
horses residing | 4 |
ammonium acetate | 4 |
global spread | 4 |
detected via | 4 |
multiple groups | 4 |
zooepidemicus strain | 4 |
experimentally confirmed | 4 |
intracellular calcium | 4 |
quality control | 4 |
genome using | 4 |
rna world | 4 |
research involving | 4 |
growth rate | 4 |
specific primers | 4 |
passage experiments | 4 |
hcv infection | 4 |
region corresponding | 4 |
using ingenuity | 4 |
native virions | 4 |
small subset | 4 |
targeted proteomics | 4 |
igg assay | 4 |
now show | 4 |
dodecyl sulfate | 4 |
checkpoint response | 4 |
first confirmed | 4 |
weeks postimmunization | 4 |
using rna | 4 |
arturo title | 4 |
antibody titer | 4 |
living cells | 4 |
either directly | 4 |
conserved epitopes | 4 |
long noncoding | 4 |
different branches | 4 |
infect humans | 4 |
cultured alone | 4 |
bmdcs derived | 4 |
potential antiviral | 4 |
mm iptg | 4 |
cells markedly | 4 |
human populations | 4 |
heterosubtypic protections | 4 |
young children | 4 |
pathogenic sars | 4 |
bronchial submucosal | 4 |
host transcriptome | 4 |
evolutionary scenario | 4 |
ross river | 4 |
rinderpest virus | 4 |
activated cd | 4 |
recent advances | 4 |
acyl carrier | 4 |
body plethysmography | 4 |
accessory proteins | 4 |
asymptomatic transmission | 4 |
risk mitigation | 4 |
small hydrophobic | 4 |
virus strains | 4 |
virus world | 4 |
useful tool | 4 |
lavage fluid | 4 |
million people | 4 |
humanely euthanized | 4 |
host mhc | 4 |
various concentrations | 4 |
may therefore | 4 |
pearson correlation | 4 |
mutations within | 4 |
allowing us | 4 |
molecule inhibitors | 4 |
therapeutic target | 4 |
coronavirus hku | 4 |
patience gp | 4 |
specific gene | 4 |
cytokine responses | 4 |
convalescent donors | 4 |
influenza transmission | 4 |
flow rate | 4 |
mdbk cells | 4 |
lucifugus skin | 4 |
novel host | 4 |
views expressed | 4 |
tail subunit | 4 |
interface footprint | 4 |
potential use | 4 |
two horses | 4 |
results show | 4 |
coronavirus oc | 4 |
hcov oc | 4 |
coli cells | 4 |
experimental adaptation | 4 |
like gene | 4 |
unknown viral | 4 |
plsb inhibition | 4 |
weighted gene | 4 |
structural analysis | 4 |
brief culture | 4 |
culture supernatant | 4 |
tryptose phosphate | 4 |
many years | 4 |
dmv interior | 4 |
analysis shows | 4 |
diverse virus | 4 |
lesions compared | 4 |
virus interaction | 4 |
mrna splicing | 4 |
transcribed using | 4 |
cov disease | 4 |
bd pharmingen | 4 |
tested positive | 4 |
bipartite network | 4 |
differential scanning | 4 |
sequenced using | 4 |
cell recruitment | 4 |
drug candidates | 4 |
synthesis regulation | 4 |
syndrome virus | 4 |
rna accumulation | 4 |
nucleotide level | 4 |
rna transport | 4 |
virus must | 4 |
exudative phase | 4 |
including microrna | 4 |
animal health | 4 |
mers spike | 4 |
early studies | 4 |
study showed | 4 |
knowledge base | 4 |
iron acquisition | 4 |
virus stocks | 4 |
virus detection | 4 |
shows potential | 4 |
virus isolate | 4 |
plasmid containing | 4 |
early time | 4 |
samples using | 4 |
gas infection | 4 |
laboratory accident | 4 |
drugs will | 4 |
stably expressing | 4 |
previously found | 4 |
streptococcal vaccine | 4 |
tris ph | 4 |
ppgpp synthesis | 4 |
mean od | 4 |
competitive fitness | 4 |
using gene | 4 |
powered air | 4 |
flow cells | 4 |
rna samples | 4 |
host transcriptional | 4 |
mm formic | 4 |
lung fibrosis | 4 |
lung damage | 4 |
fn interaction | 4 |
three different | 4 |
influenza research | 4 |
initiate infection | 4 |
mammalian viruses | 4 |